Loginov A S, Dzhalalov K D, Blok Iu E, Bendikov E A, Ausheva L Kh
Ter Arkh. 1986;58(2):73-6.
Fifty-seven patients with chronic liver diseases of different etiology were treated with catergen ((+)-cyanidanol 3) given in a dose of 1.5 g (3 tablets) a day throughout 3 months. The findings were compared with those derived in the control groups of patients (82) who received vitamins or essentiale. It was shown that catergen significantly improved some biochemical characteristics of the blood and indicators of the antipyrine test in patients with compensated liver cirrhosis of the viral and alcoholic etiology. In patients with alcoholic cirrhosis, catergen, like essentiale, exerted an inhibitory effect on lipid peroxidation in the liver. There were no significant differences in the biochemical characteristics of the blood in patients with chronic alcoholic hepatitis treated with catergen and control group patients. In patients with primary biliary cirrhosis, catergen exerted an insignificant symptomatic effect but in single cases. The side dyspeptic effects which demanded the drug withdrawal were only recorded in 2 patients. It is concluded that catergen may be used in the treatment of virus- and alcohol-induced chronic liver diseases of moderate activity.
57例不同病因的慢性肝病患者接受了卡他林（（+）-氰定醇3）治疗，剂量为每日1.5克（3片），持续3个月。将结果与接受维生素或肝得健的对照组患者（82例）的结果进行比较。结果表明，卡他林显著改善了病毒和酒精性病因的代偿性肝硬化患者的一些血液生化特征和安替比林试验指标。在酒精性肝硬化患者中，卡他林与肝得健一样，对肝脏脂质过氧化有抑制作用。接受卡他林治疗的慢性酒精性肝炎患者与对照组患者的血液生化特征无显著差异。在原发性胆汁性肝硬化患者中，卡他林仅在个别病例中产生不明显的对症作用。仅2例患者记录到需要停药的消化不良副作用。结论是，卡他林可用于治疗病毒和酒精引起的中度活动性慢性肝病。
